Middle East & Africa Cancer Immunotherapy Market Size & Outlook
Middle East & Africa cancer immunotherapy market, 2018-2030 (US$M)
Related Markets
MEA cancer immunotherapy market highlights
- The MEA cancer immunotherapy market generated a revenue of USD 2,717.0 million in 2023.
- The market is expected to grow at a CAGR of 7.1% from 2024 to 2030.
- In terms of segment, monoclonal antibodies was the largest revenue generating product in 2023.
- Oncolytic Viral Therapies and Cancer Vaccines is the most lucrative product segment registering the fastest growth during the forecast period.
- Country-wise, Kuwait is expected to register the highest CAGR from 2024 to 2030.
MEA data book summary
| Market revenue in 2023 | USD 2,717.0 million |
| Market revenue in 2030 | USD 4,404.1 million |
| Growth rate | 7.1% (CAGR from 2023 to 2030) |
| Largest segment | Monoclonal antibodies |
| Fastest growing segment | Oncolytic Viral Therapies and Cancer Vaccines |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Monoclonal Antibodies, Check Point Inhibitors, Oncolytic Viral Therapies and Cancer Vaccines |
| Key market players worldwide | Pfizer Inc, AstraZeneca PLC, Merck & Co Inc, Roche Holding AG, Bristol-Myers Squibb Co, Novartis AG ADR, Eli Lilly and Co, Johnson & Johnson, Immunocore Holdings PLC ADR |
Other key industry trends
- In terms of revenue, MEA region accounted for 2.2% of the global cancer immunotherapy market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 59,131.5 million by 2030.
Monoclonal antibodies was the largest segment with a revenue share of 66.44% in 2023. Horizon Databook has segmented the Middle East & Africa cancer immunotherapy market based on monoclonal antibodies, check point inhibitors, oncolytic viral therapies and cancer vaccines covering the revenue growth of each sub-segment from 2018 to 2030.
Rising demand for effective and cost-efficient cancer therapies is one of the major factors contributing to the growth of the cancer immunotherapy drugs market in MEA. Factors such as increase in the need for improved healthcare infrastructure and high burden of diseases, such as cancer, are expected to boost the demand for improved treatment strategies.
MEA is increasingly focusing on genetic counselling and risk assessment for different cancer types, thereby driving personalized healthcare. Rising consumer awareness about cancer is likely to have a positive influence on market growth. Premium pricing of drugs indicates the growing need for favorable reimbursement policies, especially in low- and middle-income countries.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cancer Immunotherapy Market Scope
Cancer Immunotherapy Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
MEA cancer immunotherapy market size, by country, 2018-2030 (US$M)
Middle East & Africa Cancer Immunotherapy Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
